| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Kura Oncology to Participate in Two Upcoming Investor Conferences
By: GlobenewsWire - 22 Nov 2022Back to overview list

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences:

  • A fireside chat at the Evercore ISI HealthCONx Conference at 12:35 p.m. ET / 9:35 a.m. PT on November 29, 2022; and

  • A fireside chat at the JMP Securities Hematology and Oncology Summit at 12:20 p.m. ET / 9:20 a.m. PT on December 7, 2022.

Audio webcasts of both fireside chats will be available in the Investors section of Kura’s website at, with archived replays available following both events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC). Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3K? inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3K? pathways. The Company has also initiated a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in EGFR-mutant non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at


Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803

Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932

Jason Spark
Managing Director
Evoke Canale
(619) 849-6005

Related companies:Kura Oncology, Inc
Copyright 2022 GlobenewsWire Back to overview list
to the top ↑
{literal} {/literal}